Bill Shimp, Author at Jupiter Life Science Consulting

16 May Addressing the opioid crisis: abuse deterrent-formulations and the future of pain management

Posted at 13:13h in News

The opioid epidemic in the United States is a serious national crisis that affects public health as social and economic welfare. From 1999 to 2017, more than 700,000 people died from a drug overdose; of which, 218,000 were related to prescription opioid use/abuse.1 In 2017...

22 Apr Digital pills: The future of oral therapy?

Posted at 18:40h in Blog

Patient adherence is critical to improving health outcomes and reducing costs to the health care system1. However, patient adherence remains a significant challenge, particularly in chronic diseases requiring frequent and ongoing pharmaceutical treatment. Health care professionals and health systems recognize this as a significant and...

26 Feb Real World Data in the Regulatory & Reimbursement process – Implications for value and access

Posted at 18:36h in Blog

From mobile devices to wearables and biosensors, digital innovation has led to an exponential increase in the availability of health-related data. While the healthcare market has traditionally been slow to adopt digital innovations (in 2017 14% of US clinician offices still relied on paper medical records) there are now a multitude of ways healthcare companies...

18 Feb Implications of Pharmaceutical Price Transparency in Television Advertising

Posted at 19:24h in Blog

In May of 2018, the Trump administration released a proposal which it described as a blueprint to address rising pharmaceutical costs. The proposal, American Patients First, consisted of four key strategies for reform (you can read the full Jupiter assessment here) including an effort to...

11 Feb The impact of legislative and public scrutiny on pharmaceutical price increases

Posted at 16:10h in Blog

In many respects, 2018 appeared as though Donald Trump might make good on his key campaign promise to curb increasing pharmaceutical prices. With public and legislative scrutiny of manufacturer pricing practices continually increasing, the Trump White House released their “blueprint” for addressing rising drug costs,...

04 Feb The increasing role of state legislature in pharmaceutical pricing and access

Posted at 15:59h in Blog

As public and political scrutiny of drug prices continues, pharmaceutical companies are increasingly encountering new governmental efforts to control rising drug costs. At the federal level, this scrutiny resulted in the publication of the Trump administration’s American Patients First blueprint last year. While the major...

Author: Bill Shimp